近日，翔宇医疗在互动平台向投资者表示，公司以积极的态度、谨慎的方式推进投资并购事宜，公司投 融资工作有序推进中。康复行业格局较分散，标的公司的规模体量均不大，公司视具体情况采取整合拓 展或参股并购的方式实现外延式发展。研发投入到产出、产品力到销售力，均需要一定的时间；同时， 招投标等需要一定的周期。 自2021年上市以来，作为康复医疗器械领域的企业，翔宇医疗的业绩近年来开始回落。不过，值得一提 的是，在增收不增利的情况下，翔宇医疗研发费用却在增长。《财经新康养》注意到，翔宇医疗在研发 成果上聚焦在康养机器人和脑机接口两大领域。 翔宇医疗当前脑机接口相关产品在养老机构与居家场景的落地情况如何？助浴专用护理机器人何时能实 现商业化？公司如何平衡前沿技术投入与盈利压力？针对上述问题，11月25日下午，《财经新康养》通 过电话和邮件联系翔宇医疗，截至发稿前未获回复。 翔宇医疗营收微增利润承压 总部位于河南省安阳市的翔宇医疗所处大行业为医疗器械行业，细分行业为康复医疗器械行业。公司致 力于康复医疗器械研发、生产、销售和服务，为全国各级医疗机构、养老机构、残疾人康复中心、福利 院、教育系统等机构以及家庭提供系列康复产品及 ...

Investment Rating - The report rates the medical device industry as "Outperforming the Market" [1][5]. Core Insights - 2026 is expected to be a year of value reconstruction for China's medical device sector, driven by policy support, innovation, and recovery of domestic demand [1][3]. - The industry is witnessing a shift from "approval optimization" to "payment optimization," with regulatory improvements supporting the innovation of high-end medical devices [1][3]. - The current market fundamentals show signs of a turning point, while institutional holdings are at historical lows, indicating potential investment opportunities [1][3]. Summary by Sections Overall Medical Device Situation - In the first three quarters of 2025, the SW medical device index reported total revenues of 178.4 billion yuan, a year-on-year decrease of 2.29%, primarily affected by low-value consumables and IVD [15]. - The overall net profit for the same period was 26.7 billion yuan, down 13.99%, with high-value consumables showing improved profitability [15][20]. Medical Equipment - The recovery of procurement orders is expected to peak in Q4 2025 to Q1 2026, driven by improved funding and the "old-for-new" policy [66]. - The domestic government procurement income is stabilizing, while overseas revenue is still in a low base phase, indicating significant growth potential [66]. - The report highlights that the economic benefits of equipment procurement are becoming evident, with domestic high-end equipment showing competitive pricing [71]. Innovation in Medical Devices - The report emphasizes three main investment themes: government support, recovery of domestic demand, and accelerated overseas expansion [3][66]. - The innovation cycle is expected to accelerate, with a focus on companies that possess core competitiveness and a global perspective [3][66]. Market Trends - The report notes that the medical device sector is gradually stabilizing, with companies adapting to procurement pressures and showing signs of performance recovery [54]. - The overseas revenue share for medical device companies is increasing, with significant growth opportunities in regions with lower per capita equipment numbers [32][66].

Core Insights - The company reported a total revenue of 537 million yuan for the first three quarters of 2025, representing a year-on-year growth of 6.00% [1] - The net profit attributable to shareholders for the same period was 43.98 million yuan [1] - In Q3 2025, the company achieved a revenue of 178 million yuan, with a year-on-year increase of 5.5%, and a net profit of 8.59 million yuan [1] Financial Performance - Total revenue for the first three quarters: 537 million yuan, up 6.00% year-on-year [1] - Net profit attributable to shareholders: 43.98 million yuan [1] - Q3 2025 revenue: 178 million yuan, up 5.5% year-on-year [1] - Q3 2025 net profit: 8.59 million yuan; net profit after deducting non-recurring items: 6.91 million yuan [1] Research and Development - The company increased its R&D investment, with expenses reaching 125 million yuan in the first three quarters, a year-on-year growth of 8.85% [1] - The company added 87 new patents, including 30 new invention patents, bringing the total to 1,936 patents [1] - The company also achieved 29 new provincial-level scientific and technological achievements, totaling 277 [1] - The company won the third prize in military scientific and technological progress awards [1] Product Development and Market Expansion - The company is focusing on brain-machine interface technology, with multiple products approved for use [1] - Over 80 large hospitals are currently using the company's brain-machine interface rehabilitation devices [1] - New products equipped with brain-machine interface technology are expected to significantly boost the company's performance in 2026 [1]

Group 1: Xiangyu Medical - The brain-computer interface (BCI) shows clear prospects in rehabilitation, potentially shifting patients from "passive rehabilitation" to "active rehabilitation," reducing labor costs and improving outcomes [1] - The company has an integrated advantage with "BCI technology + proprietary rehabilitation equipment," having obtained registration for two EEG collection devices, with over 20 devices expected to be certified by year-end and nearly 100 by the end of next year [1] - More than 50 large hospitals are currently using the company's equipment, which is expected to contribute to performance in 2025 and significantly enhance performance in 2026 [1] - R&D investment has increased by 38.80% year-on-year, with 117 new patents added, totaling 1,933 patents, including several related to BCI technology [1] - The sales model starts with partnerships with top-tier hospitals to create benchmarks, gradually extending to grassroots levels and eventually entering the home market [1] Group 2: Fenghua Gaoke - In the first half of 2025, the company aims to achieve record highs in product sales and revenue through cost reduction, efficient innovation, and new market development [2] - Automotive electronics sales increased by 39% year-on-year, communications by 22%, industrial control by 21%, and sales to the top ten customers grew by 27% [2] - Supercapacitor sales surged by 138%, with breakthroughs in emerging markets such as computing power, energy storage, intelligent robotics, and low-altitude economy [2] - The company has launched new products including medium and high-voltage MLCCs, MI series alloy resistors, and S series automotive-grade thick film precision resistors, emphasizing high reliability, miniaturization, and high precision [2] - A pricing strategy based on market supply and demand has been implemented to optimize product structure and improve gross margins [2] - The company has initiated a successor plan for talent management and is attracting core technical teams [2] - A "1+2+4+4+N" strategy has been established to promote high-quality development through seven strategic initiatives and various special projects [2]

Core Viewpoint - The article discusses the recent surge in stock prices of Innovate Medical, driven by the brain-computer interface (BCI) technology, while highlighting the disconnect between the industry's current stage and market expectations [2][4]. Group 1: Company Performance - In the first half of 2025, Innovate Medical reported revenue of 402 million yuan, a year-on-year decline of 1.60%, and a net loss of 12.88 million yuan [4]. - Since 2019, Innovate Medical has experienced continuous net profit losses, totaling over 1.76 billion yuan from 2019 to 2024 [4]. - The company attributed its reduced losses in the first half of 2025 to increased medical insurance reimbursements and decreased credit impairment losses, without disclosing specific reasons for the losses [5]. Group 2: Subsidiary Performance - Among the subsidiaries of Innovate Medical, two out of three reported losses, with Kanghua Hospital losing 681,000 yuan and Futen Hospital losing 3.86 million yuan [5]. - The significant driver behind Innovate Medical's stock price increase is its subsidiary, Boling Brain Machine (Hangzhou) Technology Co., which focuses on BCI technology but has not yet launched products commercially [5]. Group 3: Market Dynamics - The BCI sector is currently in the preclinical research or small-scale trial phase, with unclear commercialization paths, leading to deteriorating financial statements for many companies [2][4]. - The article notes that the A-share market has a high risk preference for "hard technology," resulting in a disconnect between fundamentals and stock prices, reflecting a forward pricing mechanism for cutting-edge technologies [2]. Group 4: Regulatory and Industry Developments - On August 7, 2025, the Ministry of Industry and Information Technology and six other departments issued a policy to accelerate the development of the BCI industry, setting goals for key technological breakthroughs by 2027 and international competitiveness by 2030 [8]. - The article highlights that there is currently no benchmark enterprise in the global BCI market, but three potential leaders are emerging: technology pioneers with core technologies, clinical transformation companies with FDA approvals, and platform ecosystem companies with open-source hardware [10][11].

Group 1: Quantum Communication and Computing - A Chinese research team has achieved a breakthrough in quantum direct communication, successfully establishing a 300-kilometer quantum communication network with a fidelity of over 85% [1] - The global quantum industry is projected to grow from $5 billion in 2024 to over $800 billion by 2035, with a CAGR of 59% [2] - Companies like Geer Software and Keda Guokai are actively developing quantum technologies, including anti-quantum encryption and quantum key distribution [2] Group 2: Analog Chip Market - The global analog chip inventory cycle is believed to have bottomed out after nearly six quarters of adjustment, driven by demand in consumer electronics, automotive electronics, and industrial control [3] - Companies such as Shengbang and Sirepu are leading in the analog integrated circuit design industry, with extensive product offerings and significant customer bases [4] Group 3: Brain-Computer Interface (BCI) Development - The establishment of China's first clinical brain-computer interface ward marks a significant step towards the commercialization of BCI technology, with plans for multiple invasive products to undergo clinical trials by 2030 [5] - Companies like Chengyitong and Sanbo Neuroscience are advancing in both invasive and non-invasive BCI technologies, with products expected to launch in 2025 [6] Group 4: Stablecoin Regulation in Hong Kong - Hong Kong's Stablecoin Ordinance has officially become law, establishing a licensing system for stablecoin issuers and promoting financial innovation while maintaining stability [7] - Companies like Newland and Youbuxun are developing digital currency acceptance solutions and have obtained necessary licenses for cross-border payment operations [8] Group 5: Humanoid Robot Industry - The humanoid robot sector is experiencing a surge in orders, prompting companies to expand production capacity, with significant growth expected in 2025 [9][10] - Companies such as Far East and Zhongding are supplying critical components for humanoid robots, enhancing their capabilities and durability [11] Group 6: Low-altitude Economy - The low-altitude economy is gaining traction, with policies supporting its development and a projected market potential of over a trillion yuan in the coming years [12] - Companies like Zongshen Power and Lais Information are positioning themselves in the low-altitude sector, providing solutions for general aviation and air traffic management [13]

Group 1 - Xiangyu Medical is actively engaged in the fields of rehabilitation robots and brain-computer interfaces, focusing on four directions: movement, therapy, assessment, and nursing [1] - The company has over 20 ongoing projects related to rehabilitation robots, with a portable exoskeleton walking robot expected to obtain certification within the year [1] - Xiangyu Medical has established the Sun-BCI Lab for brain-computer interfaces, covering four product categories, with some products expected to receive certification in the second half of the year [1] Group 2 - The National Healthcare Security Administration has released a guideline for pricing projects related to neurological medical services, supporting the realization of high-level medical technology value [1] - Hubei province has taken the lead in implementing specific pricing, providing a reference template for other regions [1] - The company possesses core algorithm intellectual property and has independently developed high-precision multimodal brain-computer interface rehabilitation devices [1] Group 3 - Xiangyu Medical's testing and inspection center is equipped with advanced testing equipment, offering one-stop testing services [1] - The company also provides rehabilitation equipment for children and multidisciplinary pelvic floor products [1] - The company is scheduled to disclose its first-quarter report for 2025 on April 25 [1]